Business Wire

87% of Institutional Investors Have Declined or Reconsidered Fund Commitments Due to AML/KYC Concerns

17.11.2025 14:30:00 CET | Business Wire | Press Release

Share

Nearly nine-in-10 (87%) limited partners (LPs) have declined or reconsidered a fund allocation due to anti-money laundering and Know Your Customer (AML/KYC) concerns, underscoring just how significant compliance has become as a gatekeeping item for fundraising.

According to a new study by CSC, the leading provider of global business administration and compliance solutions, general partners (GPs) are already feeling the strain. Almost two-thirds (63%) report losing investors or reinvestments due to AML/KYC shortcomings, most commonly from documentation gaps (61%) and onboarding delays (24%).

CSC surveyed 200 GPs and 200 LPs across North America, Europe, the U.K., and Asia Pacific to capture views on the evolving compliance landscape.1 The findings are detailed in CSC’s report, “Beyond Compliance: How AML/KYC is Redefining Investor Confidence.”

The study found that LPs are setting the pace when it comes to AML/KYC. 88% said they’re more likely to invest in a manager with a formal AML/KYC program, even before regulations mandate it.

Top operational due diligence risks cited by LPs include inconsistent practices across jurisdictions (82%), lack of independent oversight (48%), and reliance on manual or paper-based compliance (41%). Nearly all LPs (97%) expect AML/KYC to become a critical, central element of due diligence within three years.

“AML has evolved from a back-office compliance task to a front-line determinant of fundraising success,” says Chalene Francis, senior executive director and head of Fund Services, North America at CSC. “LPs have options, and they’re backing managers who treat compliance as non-negotiable. Managers must prepare early and work closely with service providers to avoid the friction points that slow onboarding. If you wait until fundraising is already underway to get AML-ready, you risk losing both investors and reinvestments.”

With significant AML and KYC regulatory changes underway globally, many GPs acknowledge they’re not fully prepared. Globally, fewer than half (47%) of managers feel ready for new AML/KYC rules and developments taking effect from 2026 onward, for instance, including the launch of the EU’s Anti-Money Laundering Authority that will assume direct supervisory powers over high-risk financial entities.

To close the gap, fund managers are leaning on outsourcing and technology. More than nine in 10 (91%) already outsource some or all AML/KYC functions, with nearly three-quarters reporting cost savings of between 10-30%. Over the next year, 83% of GPs plan to expand outsourcing while 59% expect to increase technology investments.

“Outsourcing and technology have become essential for keeping AML/KYC standards consistent across jurisdictions,” adds Laettitia Vika, head of Investor Services, Europe at CSC. “With weekly sanction list updates, inconsistent local documentation practices, and varying cultural expectations, firms need teams that can balance automation with human judgment. Partnering with the right service provider not only helps reduce onboarding friction, but also brings the expertise, efficiency, and consistency that strengthen investor confidence.”

To receive a copy of CSC’s report,Beyond Compliance: How AML/KYC is Redefining Investor Confidence,” contact us at cscteam@cdrconsultancy.com.

About CSC

CSC is the leading provider of business administration and compliance solutions, offering industry-leading expertise and unmatched global reach to alternative fund managers and capital markets participants. Leveraging deep institutional experience and a tailored approach, CSC delivers a comprehensive suite of fund administration, trust, agency, and compliance services to support a wide range of private and public market transactions, complex fund strategies, and scalable operations.

As the trusted partner of choice for more than 70% of the PEI 300 and 90% of the Fortune 500®, CSC helps clients navigate operational and transactional complexities across more than 140 jurisdictions and various asset classes. With extensive worldwide capabilities, our expert teams provide solutions tailored to each client’s needs. Privately held and professionally managed since 1899, we combine global reach, local expertise, and innovative solutions to help our clients succeed.

We are the business behind business®. Learn more at cscglobal.com.

1CSC, in partnership with Pure Profile, surveyed 200 GP and 200 LP senior fund professionals operating in Europe, the U.K., North America, and Asia Pacific to capture their views on the evolving compliance landscape. Respondents were equally split between North America, Asia Pacific, and Europe.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251117227240/en/

Contacts

For more information:
Citigate Dewe Rogerson
Hassan Ali | Thomas Dalton
cscteam@cdrconsultancy.com

CSC
Katie Scott-Kurti
Head of Brand & Communications
katie.scottkurti@cscglobal.com
CSC News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fpress%2F&esheet=54358104&newsitemid=20251117227240&lan=en-US&anc
hor=CSC+News+Room&index=4&md5=f4cb8f7bfc7c978ac68e4660af99d114

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press Release

Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim

Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press Release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press Release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press Release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye